Cough
Conditions
Keywords
functional brain imaging, ATP, Capsaicin, Refractory cough
Brief summary
Persistent cough is a distressing symptom for people with respiratory disorders. Patients also often experience an ongoing urge-to-cough that prompts coughing, and which fails to resolve the sensation. Understanding how the brain controls cough and the urge-to-cough could lead to new cough suppressing therapies. The overall objective of this project is to use functional brain imaging (fMRI) to identify brain regions that are involved in the exaggerated urge-to-cough in humans with chronic cough. Our focus will be on the brainstem where information from the airways first arrives in the central nervous system.
Detailed description
Peripheral effects of ATP via P2X3 receptors ATP has been shown to be a tussive agent particularly on chronic cough patients who were more sensitive than non-cough subjects to inhaled ATP. ATP has been shown to augment the cough response to capsaicin in patients with asthma. Gefapixant at a single oral dose of 50 mg did not modulate capsaicin cough responses in normal volunteers and chronic cough subjects while inhibiting ATP-induced cough particularly in chronic cough subjects. These observations would suggest that ATP has a direct effect on a subset sensory neurons that evoke coughing through the activation of P2X3 receptors. The use of fMRI to provide insights into the peripheral and central sites of activation by ATP/P2X3 activation We have generated functional brain imaging (fMRI) data to suggest that the different brain circuits in receipt of nodose and jugular ganglia neuron inputs (as identified in animal studies) are conserved in humans. When inhaled, the tussigenic compound capsaicin (from hot chili peppers) indiscriminately stimulates both nodose and jugular chemosensitive afferents and we have published that capsaicin inhalation produces brain activations in the primary sensory, anterior and mid-insula, cingulate, premotor, motor and orbitofrontal cortices. These regions are presumed to encode perceptual awareness of airway irritation, and the associated emotional, cognitive and behavioral (motor) consequences. For example, activity in the human primary sensory cortex (which receives jugular ganglia inputs in animal studies) correlates with an individual's perception of airway irritation (their perceived need/ urge to cough) while activity in the insula (in receipt of nodose inputs) relates closely to the actual magnitude of the delivered stimulus independent of perception. We have now built upon these published findings by using high resolution brainstem fMRI during the inhalation of ATP (expected to only activate P2X2/3 expressing nodose-derived airway afferents) versus capsaicin (expected to activate both jugular and nodose chemosensitive afferents). Our results are striking and reveal that ATP inhalation evokes an in increased signal level in the brainstem regions corresponding to the nTS, while capsaicin inhalation produces activations in both the nTS and in an area of the dorsal spinal trigeminal nucleus on the lateral margins of the brainstem that contains the paratrigeminal nucleus. Indeed, our healthy participants did not cough as much to ATP compared to capsaicin, consistent with studies cough in animals and humans and the relatively poor cough-evoking properties of ATP in healthy humans. However, the perception of airway irritation was identical between ATP and capsaicin stimuli. We believe that cough production will ultimately be dependent upon activation of the neural circuit that integrates in the paratrigeminal nucleus (i.e.' the jugular afferent pathway) and therefore we hypothesize that there is an upregulation of the capacity of ATP to act via jugular ganglia pathways in chronic cough patients. The fMRI studies described above provide an exciting opportunity to assess for the first time which primary airway afferent pathways are likely excited or sensitized by ATP and, in turn, what aspects of the central processing of airway sensory information is altered by ATP. We have reported previously that patients with chronic cough display functional brain responses consistent with a state of central sensitization that closely resembles the central sensitization accompanying chronic pain. We will extend upon these findings by determining whether ATP-sensitive pathways in the brainstem and brain are altered in patients with chronic cough, and in doing so provide insight into whether ATP effects vagal afferent processing through an interaction with nodose and/ or jugular neural pathways.
Interventions
Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough
Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough
Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)
Sponsors
Study design
Intervention model description
The experiment will consist of two sessions. The first session will involve questionnaires, followed by measures of sensitivity and behavioural responses to tussive (cough evoking) stimulation. The second session will involve functional brain imaging measures of responses to tussive stimulation.
Eligibility
Inclusion criteria
* Patients with physician diagnosed chronic refractory cough (cough lasting \>8 weeks). * \> 18 years of age * Must be cognitively impaired
Exclusion criteria
* People with contraindications to MRI scanning (i.e. metal implants, claustrophobia). * History of uncontrolled asthma or chronic respiratory disease (other than refractory cough). * Evidence of an allergic reaction to capsaicin (chilli). * Pregnant women. * Smoking, current or recent history (last 6 months).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Brainstem Neural Activations to Capsaicin | fMRI was performed in a single session on the day of the cough challenge testing session and not more than seven days after. | fMRI will be used to determine the location and magnitude of neural responses in the brainstem during Capsaicin inhalation: in particular, the nucleus of the solitary tract and the paratrigeminal nucleus. fMRI non-invasively measures Blood Oxygen Level Dependent (BOLD) signals in the brain which can be used to identify regions of the brain that increase activity associated with the inhaled stimuli. BOLD signals detected are to be reported as % BOLD signal change in response to Capsaicin greater than control saline. |
| Brainstem Neural Activations to ATP | fMRI was performed in a single session on the day of the cough challenge testing session and not more than seven days after. | fMRI will be used to determine the location and magnitude of neural responses in the brainstem during ATP inhalation: in particular, the nucleus of the solitary tract and the paratrigeminal nucleus. fMRI non-invasively measures Blood Oxygen Level Dependent (BOLD) signals in the brain which can be used to identify regions of the brain that increase activity associated with the inhaled stimuli. BOLD signals detected are to be reported as % BOLD signal change in response to ATP greater than control saline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to Capsaicin | Thresholds for cough sensitivity were measured during a 1 hr session prior to fMRI scanning | Participant responses (cough and the urge-to-cough) evoked by Capsaicin will be measured by counting audible coughs to doubling doses of Capsaicin and by asking participants to rate their perception of urge-to-cough using visual analogue scales (VAS) to each dose. Thresholds for cough sensitivity are to be reported as microM. Cu is the threshold dose required to elicit a non-zero urge-to-cough rating. C2 is the threshold dose required to elicit two audible coughs. Smax is the largest dose that could be inhaled for 24s without eliciting an audible cough. fMRI dose was the dose used during fMRI scanning. |
| Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATP | Thresholds for cough sensitivity were measured during a 1 hr session prior to fMRI scanning | Participant responses (cough and the urge-to-cough) evoked by ATP will be measured by counting audible coughs to doubling doses of ATP and by asking participants to rate their perception of urge-to-cough using visual analogue scales (VAS) to each dose. Thresholds for cough sensitivity are to be reported as milliM. Cu is the threshold dose required to elicit a non-zero urge-to-cough rating. C2 is the threshold dose required to elicit two audible coughs. Smax is the largest dose that could be inhaled for 24s without eliciting an audible cough. fMRI dose was the dose used during fMRI scanning. |
| Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | Urge-to-cough ratings were reported during the 1 hour cough challenge testing session and during the subsequent fMRI scanning session | Participant responses (cough and the urge-to-cough) evoked by ATP will be measured by counting audible coughs to doubling doses of ATP and by asking participants to rate their perception of urge-to-cough using visual analogue scales (VAS) to each dose.Urge-to-cough score is reported by the participant using a Bog scale ranging from 0 (no urge) to 10 (most intense urge imaginable) where the higher score, the worse the outcome. Cu is the threshold dose required to elicit a non-zero urge-to-cough rating. C2 is the threshold dose required to elicit two audible coughs. Smax is the largest dose that could be inhaled for 24s without eliciting an audible cough. fMRI dose was the dose used during fMRI scanning. |
Countries
Australia
Participant flow
Recruitment details
All participants were initially screened via telephone interviews for inclusion and exclusion criteria and gave written, informed consent prior to study enrolment. Refractory and unexplained chronic cough were diagnosed by a respiratory or laryngology specialist or general practitioner and inclusion required cough of at least 6 months duration with no abnormalities on chest X-ray or CT scan.
Participants by arm
| Arm | Count |
|---|---|
| Chronic Cough Participant Twenty-nine (29) Idiopathic chronic cough patients, defined as refractory to disease modifying therapies (eg anti-asthma medications), were recruited.
Participants attended two sessions. In the first they inhaled in a single breath nebulized solutions of increasing doses of Adenosine Triphosphate (ATP; 0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds.
In the second session, participants underwent functional brain imaging (fMRI) for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin. | 29 |
| Healthy Control Participant Twenty-nine (29) appropriately age and sex matched healthy non-smoking individuals were recruited as the comparison group.
Participants attended two sessions. In the first they inhaled in a single breath nebulized solutions of increasing doses of Adenosine Triphosphate (ATP; 0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds.
In the second session, participants underwent functional brain imaging (fMRI) for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin. | 29 |
| Total | 58 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Withdrawal by Subject | 1 | 1 |
Baseline characteristics
| Characteristic | Healthy Control Participant | Total | Chronic Cough Participant |
|---|---|---|---|
| Age, Continuous | 59.7 years STANDARD_DEVIATION 12 | 60.1 years STANDARD_DEVIATION 12 | 60.6 years STANDARD_DEVIATION 12.2 |
| Hull Cough Hypersensitivity Questionnaire (HARQ) score | 2.3 units on a scale STANDARD_DEVIATION 2.8 | 17.5 units on a scale STANDARD_DEVIATION 18.1 | 33.1 units on a scale STANDARD_DEVIATION 13.1 |
| Leicester Cough Questionnaire (LCQ) score | 20.8 units on a scale STANDARD_DEVIATION 0.3 | 17.3 units on a scale STANDARD_DEVIATION 4.5 | 13.9 units on a scale STANDARD_DEVIATION 3.6 |
| Newcastle Laryngeal Hypersensitivity Questionnaire (LHQ) score | 20.1 units on a scale STANDARD_DEVIATION 1.1 | 17.5 units on a scale STANDARD_DEVIATION 3.5 | 14.8 units on a scale STANDARD_DEVIATION 3 |
| Race and Ethnicity Not Collected | — | 0 Participants | — |
| Region of Enrollment Australia | 29 participants | 58 participants | 29 participants |
| Sex: Female, Male Female | 19 Participants | 38 Participants | 19 Participants |
| Sex: Female, Male Male | 10 Participants | 20 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 29 | 0 / 29 |
| other Total, other adverse events | 0 / 29 | 0 / 29 |
| serious Total, serious adverse events | 0 / 29 | 0 / 29 |
Outcome results
Brainstem Neural Activations to ATP
fMRI will be used to determine the location and magnitude of neural responses in the brainstem during ATP inhalation: in particular, the nucleus of the solitary tract and the paratrigeminal nucleus. fMRI non-invasively measures Blood Oxygen Level Dependent (BOLD) signals in the brain which can be used to identify regions of the brain that increase activity associated with the inhaled stimuli. BOLD signals detected are to be reported as % BOLD signal change in response to ATP greater than control saline.
Time frame: fMRI was performed in a single session on the day of the cough challenge testing session and not more than seven days after.
Population: Cough participants displayed characteristic signs and symptoms of refractory chronic cough. 1 participant from each group withdrew prior to completion of the primary endpoint investigation.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Chronic Cough Participant | Brainstem Neural Activations to ATP | %BOLD signal Change: Nucleus of the Solitary Tract | 0.04 Percent change in BOLD signal | Standard Deviation 0.47 |
| Chronic Cough Participant | Brainstem Neural Activations to ATP | %BOLD signal Change: Paratrigeminal Nucleus | 0.01 Percent change in BOLD signal | Standard Deviation 0.65 |
| Healthy Control Participant | Brainstem Neural Activations to ATP | %BOLD signal Change: Nucleus of the Solitary Tract | 0.28 Percent change in BOLD signal | Standard Deviation 0.58 |
| Healthy Control Participant | Brainstem Neural Activations to ATP | %BOLD signal Change: Paratrigeminal Nucleus | 0.58 Percent change in BOLD signal | Standard Deviation 0.71 |
Brainstem Neural Activations to Capsaicin
fMRI will be used to determine the location and magnitude of neural responses in the brainstem during Capsaicin inhalation: in particular, the nucleus of the solitary tract and the paratrigeminal nucleus. fMRI non-invasively measures Blood Oxygen Level Dependent (BOLD) signals in the brain which can be used to identify regions of the brain that increase activity associated with the inhaled stimuli. BOLD signals detected are to be reported as % BOLD signal change in response to Capsaicin greater than control saline.
Time frame: fMRI was performed in a single session on the day of the cough challenge testing session and not more than seven days after.
Population: Cough participants displayed characteristic signs and symptoms of refractory chronic cough. 1 participant from each group withdrew prior to completion of the primary endpoint investigation.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Chronic Cough Participant | Brainstem Neural Activations to Capsaicin | %BOLD signal Change: Nucleus of the Solitary Tract | 0.09 Percentage change in BOLD signal | Standard Deviation 0.6 |
| Chronic Cough Participant | Brainstem Neural Activations to Capsaicin | %BOLD signal Change: Paratrigeminal Nucleus | -0.14 Percentage change in BOLD signal | Standard Deviation 0.69 |
| Healthy Control Participant | Brainstem Neural Activations to Capsaicin | %BOLD signal Change: Nucleus of the Solitary Tract | 0.39 Percentage change in BOLD signal | Standard Deviation 0.47 |
| Healthy Control Participant | Brainstem Neural Activations to Capsaicin | %BOLD signal Change: Paratrigeminal Nucleus | 0.44 Percentage change in BOLD signal | Standard Deviation 1.06 |
Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATP
Participant responses (cough and the urge-to-cough) evoked by ATP will be measured by counting audible coughs to doubling doses of ATP and by asking participants to rate their perception of urge-to-cough using visual analogue scales (VAS) to each dose. Thresholds for cough sensitivity are to be reported as milliM. Cu is the threshold dose required to elicit a non-zero urge-to-cough rating. C2 is the threshold dose required to elicit two audible coughs. Smax is the largest dose that could be inhaled for 24s without eliciting an audible cough. fMRI dose was the dose used during fMRI scanning.
Time frame: Thresholds for cough sensitivity were measured during a 1 hr session prior to fMRI scanning
Population: Cough participants displayed characteristic signs and symptoms of refractory chronic cough.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Chronic Cough Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATP | ATP Urge to Cough threshold Cu | 1.29 milliM | Standard Error 4.27 |
| Chronic Cough Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATP | ATP Cough threshold C2 | 5.75 milliM | Standard Error 7.08 |
| Chronic Cough Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATP | ATP maximum tolerable dose Smax | 2.82 milliM | Standard Error 5.75 |
| Chronic Cough Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATP | ATP fMRI dose | 2.82 milliM | Standard Error 5.5 |
| Healthy Control Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATP | ATP fMRI dose | 12.02 milliM | Standard Error 4.47 |
| Healthy Control Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATP | ATP Urge to Cough threshold Cu | 2.75 milliM | Standard Error 3.63 |
| Healthy Control Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATP | ATP maximum tolerable dose Smax | 19.95 milliM | Standard Error 5.89 |
| Healthy Control Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATP | ATP Cough threshold C2 | 57.54 milliM | Standard Error 4.79 |
Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to Capsaicin
Participant responses (cough and the urge-to-cough) evoked by Capsaicin will be measured by counting audible coughs to doubling doses of Capsaicin and by asking participants to rate their perception of urge-to-cough using visual analogue scales (VAS) to each dose. Thresholds for cough sensitivity are to be reported as microM. Cu is the threshold dose required to elicit a non-zero urge-to-cough rating. C2 is the threshold dose required to elicit two audible coughs. Smax is the largest dose that could be inhaled for 24s without eliciting an audible cough. fMRI dose was the dose used during fMRI scanning.
Time frame: Thresholds for cough sensitivity were measured during a 1 hr session prior to fMRI scanning
Population: Cough participants displayed characteristic signs and symptoms of refractory chronic cough.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Chronic Cough Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to Capsaicin | Capsaicin Cough threshold C2 | 3.80 microM | Standard Error 4.9 |
| Chronic Cough Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to Capsaicin | Capsaicin maximum tolerable dose Smax | 0.91 microM | Standard Error 4.27 |
| Chronic Cough Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to Capsaicin | Capsaicin fMRI dose | 0.79 microM | Standard Error 4.17 |
| Chronic Cough Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to Capsaicin | Capsaicin Urge to Cough threshold Cu | 0.91 microM | Standard Error 5.25 |
| Healthy Control Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to Capsaicin | Capsaicin Urge to Cough threshold Cu | 2.00 microM | Standard Error 2.75 |
| Healthy Control Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to Capsaicin | Capsaicin Cough threshold C2 | 12.89 microM | Standard Error 2.75 |
| Healthy Control Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to Capsaicin | Capsaicin fMRI dose | 1.66 microM | Standard Error 3.39 |
| Healthy Control Participant | Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to Capsaicin | Capsaicin maximum tolerable dose Smax | 3.02 microM | Standard Error 3.47 |
Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP
Participant responses (cough and the urge-to-cough) evoked by ATP will be measured by counting audible coughs to doubling doses of ATP and by asking participants to rate their perception of urge-to-cough using visual analogue scales (VAS) to each dose.Urge-to-cough score is reported by the participant using a Bog scale ranging from 0 (no urge) to 10 (most intense urge imaginable) where the higher score, the worse the outcome. Cu is the threshold dose required to elicit a non-zero urge-to-cough rating. C2 is the threshold dose required to elicit two audible coughs. Smax is the largest dose that could be inhaled for 24s without eliciting an audible cough. fMRI dose was the dose used during fMRI scanning.
Time frame: Urge-to-cough ratings were reported during the 1 hour cough challenge testing session and during the subsequent fMRI scanning session
Population: Cough participants displayed characteristic signs and symptoms of refractory chronic cough.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Chronic Cough Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | ATP Urge to Cough rating at Cu | 2.31 Score on a scale | Standard Error 2.12 |
| Chronic Cough Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | Capsaicin fMRI urge to cough rating | 3.65 Score on a scale | Standard Error 2.06 |
| Chronic Cough Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | Capsaicin Urge to Cough rating at C2 | 4.48 Score on a scale | Standard Error 2.32 |
| Chronic Cough Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | ATP fMRI urge to cough rating | 2.90 Score on a scale | Standard Error 1.41 |
| Chronic Cough Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | ATP Urge to Cough rating at C2 | 5.03 Score on a scale | Standard Error 2.57 |
| Chronic Cough Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | Saline fMRI urge to cough rating | 0.86 Score on a scale | Standard Error 1.2 |
| Chronic Cough Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | Capsaicin Urge to Cough rating at Cu | 2.07 Score on a scale | Standard Error 2.03 |
| Healthy Control Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | Saline fMRI urge to cough rating | 0.44 Score on a scale | Standard Error 0.71 |
| Healthy Control Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | Capsaicin Urge to Cough rating at Cu | 1.61 Score on a scale | Standard Error 1.47 |
| Healthy Control Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | Capsaicin Urge to Cough rating at C2 | 6.80 Score on a scale | Standard Error 2.29 |
| Healthy Control Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | ATP Urge to Cough rating at Cu | 1.80 Score on a scale | Standard Error 1.65 |
| Healthy Control Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | ATP Urge to Cough rating at C2 | 6.43 Score on a scale | Standard Error 2.26 |
| Healthy Control Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | Capsaicin fMRI urge to cough rating | 3.89 Score on a scale | Standard Error 1.97 |
| Healthy Control Participant | Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP | ATP fMRI urge to cough rating | 3.93 Score on a scale | Standard Error 2.1 |